Aurinia Pharmaceuticals reports Q2 EPS (8c) vs. (25c) last year

Reports Q revenue $41.6M vs. $28.2M last year. “We are extremely pleased with our results in the Q2. Building on three successful quarters in a row, this represents our most successful quarter to date from a net revenue perspective,” said Peter Greenleaf, President, and CEO of Aurinia. “Strong commercial execution continues as we see further utilization of LUPKYNIS across the lupus nephritis marketplace. Moreover, we are excited by the depth of usage in nephrology and the continued expansion into rheumatology. Our marketing and selling efforts continue to produce patient start forms, or PSFs, patients on therapy, or POT, wallets shipped, and net product revenue at or near all-time highs.”